Rare disease clinical trials face a unique combination of scientific, operational, and regulatory challenges. Small patient populations, heterogeneous disease presentation, limited natural history data, and a frequent lack of validated outcome measures make evidence generation particularly complex. In this context, the robustness, relevance, and interpretability of clinical data become decisive factors for regulatory and market access success.
This white paper explores how electronic Clinical Outcome Assessments (eCOA) enable sponsors to address these challenges by reducing variability, enhancing clinical meaningfulness, and improving data quality. Drawing on expert insights and real world case studies, it illustrates how eCOA supports the generation of regulator-ready, patient relevant evidence in rare disease development, and highlights the consequences of adopting or failing to adopt such approaches.
Download the white paper 👇
